Research programme: RGD-targeted MMAE-albumin conjugates - Seattle GeneticsAlternative Names: RGD-MMAE-HSA; RGDPEG-MMAE-HSA
Latest Information Update: 07 Dec 2005
At a glance
- Originator Seattle Genetics
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer